Intensity Therapeutics Surges 196% Amid $11M Funding and Phase 3 Milestones

Introduction

Intensity Therapeutics Inc (NASDAQ: INTS) is a late-stage clinical biotechnology company developing intratumoral cancer therapies. As of October 30, 2025, INTS shares closed at $0.79, representing a 195.99 percent increase on trading volume of 123,842,776 shares. The company utilizes its proprietary DfuseRx™ platform to create formulations that combine established cytotoxic agents with amphiphilic molecules for direct injection into solid tumors.

Corporate Structure and Experience

Founded in 2012 and headquartered in Shelton, Connecticut, Intensity Therapeutics employs a specialized team of 2–10 employees. Key leadership includes:

• Lew H. Bender, President & CEO, who oversees strategic direction and clinical development
• Joe Talamo, Chief Financial Officer, responsible for financial planning and reporting
• Kimberly A. Guedes, VP Clinical Operations, who manages trial execution and site coordination
• Karen Du, Senior Manager, Clinical Operations, leading operational support for ongoing studies

This compact structure supports efficient decision-making and targeted resource allocation in the oncology sector.

Intratumoral therapy by Vladimir Fedotov

Recent Developments and News

• June 2024: Initiated the INVINCIBLE-3 Phase 3 trial in metastatic soft tissue sarcoma, comparing INT230-6 monotherapy to standard-of-care in second and third-line treatment.
• June 11, 2025: Announced pricing of a public offering of 6,675,000 shares at $0.30 per share, generating $2.00 million in gross proceeds; underwriters were granted a 45-day option for 1,001,250 additional shares. Proceeds allocated for enrollment in the INVINCIBLE-4 study, ongoing dosing in INVINCIBLE-3, and general corporate purposes.
• March 2025: Paused new patient enrollment and site activation in INVINCIBLE-3 due to funding constraints; existing participants continue dosing and monitoring.
• April 2025: Completed a securities purchase agreement that raised $2.35 million (net $1.90 million) from institutional investors.
• June 2025: Entered into an underwriting agreement with ThinkEquity LLC that raised $2.30 million (net $1.80 million).
• July 2025: Conducted an At-the-Market (ATM) offering that raised $6.60 million (net $6.30 million).
• August 7, 2025: Reported second-quarter financial results, noting over $11 million raised since Q2 2025 and a cash runway extended into the second half of 2026; images from the INVINCIBLE-4 study exhibit tumor necrosis observed eight days after INT230-6 injection.

Financial and Strategic Analysis

Intensity Therapeutics has strengthened its cash position through three capital raises in Q2–Q3 2025, securing approximately $11.3 million in gross proceeds, extending its operational runway into the second half of 2026. The June 2025 public offering under Form S-3 generated $2.0 million before expenses, while subsequent equity financings minimized burn rate and continued support for patient enrollment. The closing share price of $0.79 on October 30, 2025, reflects a 195.99 percent increase year-to-date, correlating with clinical milestones and funding progress. Strategic allocation of these funds toward patient enrollment and data readouts in INVINCIBLE-3 and INVINCIBLE-4 is integral to the company's operational objectives.

Market Position and Industry Context

Intensity Therapeutics operates within the competitive oncology sector, focusing on intratumoral immunochemotherapy, which is positioned between systemic chemotherapies and emerging immune checkpoint inhibitors. The DfuseRx™ platform's non-covalent conjugation of cisplatin, vinblastine, and amphiphiles aims to address challenges in the tumor microenvironment by enhancing drug saturation and supporting immune responses. Ongoing Phase 3 and Phase 2/3 trials in soft tissue sarcoma and triple-negative breast cancer aim to meet unmet needs where standard-of-care outcomes remain limited. As other biotech firms develop checkpoint modulators and antibody-drug conjugates, Intensity’s localized approach may provide additional strategies for patients with refractory or early-stage disease.

tl;dr

Since June 2025, Intensity Therapeutics has raised over $11 million through a public offering and equity financings, extending its cash runway into the second half of 2026. Its INVINCIBLE-3 Phase 3 sarcoma trial and INVINCIBLE-4 Phase 2/3 triple-negative breast cancer trial are ongoing, with microscopy images from June 2025 revealing tumor necrosis eight days post-treatment. Data on pathological complete response for INVINCIBLE-4 are anticipated in the second half of 2026.